MAIA Biotechnology
MAIA on NYSEAmerican. Market value $72m.
Should I look at this?
We have not checked this company yet
This is not advice.
Who owns it
None of the long-term investors we follow own it. 36 funds in all.
Largest holders overall
- Solas Capital Management$4mCut
- Alyeska Investment Group, L.P.$4m
- Vanguard Capital Management$3mAdded
- 683 Capital Management$2m
- Centric Wealth Management$1m
- Cable Car Capital, LP$741,000Cut
- Geode Capital Management$726,568Added
- Bleichroeder LP$720,000
- Renaissance Technologies$598,608New
- BlackRock$580,335Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- FGMK Business Holdings, LLCPassive investorat least 10.0%(filed with 1 related holder)Since 14 September 2024
- Vlad VitocInsider or founder9.7%Since 21 November 2025
What they said
The Reporting Person acquired the Common Stock reported in this Statement for investment purposes. The Reporting Person may in the future acquire additional Common Stock or dispose of some or all of the Common Stock held by the Reporting Person in open-market transactions or…
Read the filing - Solas Capital Management, LLCPassive investorat least 4.9%−2.2 pts(filed with 1 related holder)Since 30 June 2026
- Sergei M. GryaznovPassive investorSold down below 5%Since 31 December 2023
| Holder | Stake | Since | |
|---|---|---|---|
FGMK Business Holdings, LLC Passive investor | at least 10.0% (filed with 1 related holder) | 14 September 2024 | |
Vlad Vitoc Insider or founder | 9.7% | 21 November 2025 | What they saidThe Reporting Person acquired the Common Stock reported in this Statement for investment purposes. The Reporting Person may in the future acquire additional Common Stock or dispose of some or all of the Common Stock held by the Reporting Person in open-market transactions or… Read the filing |
Solas Capital Management, LLC Passive investor | at least 4.9%−2.2 pts (filed with 1 related holder) | 30 June 2026 | |
Sergei M. Gryaznov Passive investor | Sold down below 5% | 31 December 2023 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 7 insiders bought $985,874 of shares on the open market.
- Vitoc VladChief Executive Officer, DirectorBought
- Date
- 14 September 2026
- Shares
- 73,000
- Price
- $1.37
- Value
- $100,010
- Guerrero RamiroDirectorBought
- Date
- 10 September 2026
- Shares
- 37,595
- Price
- $1.32
- Value
- $49,516
- Guerrero RamiroDirectorBought
- Date
- 28 August 2026
- Shares
- 46,620
- Price
- $1.35
- Value
- $62,937
- Guerrero RamiroDirectorBought
- Date
- 27 August 2026
- Shares
- 78,239
- Price
- $1.39
- Value
- $108,752
- Guerrero RamiroDirectorBought
- Date
- 26 August 2026
- Shares
- 8,931
- Price
- $1.39
- Value
- $12,414
- Guerrero RamiroDirectorBought
- Date
- 24 August 2026
- Shares
- 1,794
- Price
- $1.33
- Value
- $2,386
- Guerrero RamiroDirectorBought
- Date
- 20 August 2026
- Shares
- 11,899
- Price
- $1.37
- Value
- $16,302
- Vitoc VladChief Executive Officer, DirectorBought
- Date
- 1 June 2026
- Shares
- 72,700
- Price
- $1.39
- Value
- $101,053
- Smith StanDirectorBought
- Date
- 1 June 2026
- Shares
- 75,000
- Price
- $1.34
- Value
- $100,500
- Gryaznov SergeiChief Scientific OfficerBought
- Date
- 1 June 2026
- Shares
- 2,000
- Price
- $1.35
- Value
- $2,700
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 14 September 2026 | Vitoc Vlad Chief Executive Officer, Director | Bought | 73,000 | $1.37 | $100,010 |
| 10 September 2026 | Guerrero Ramiro Director | Bought | 37,595 | $1.32 | $49,516 |
| 28 August 2026 | Guerrero Ramiro Director | Bought | 46,620 | $1.35 | $62,937 |
| 27 August 2026 | Guerrero Ramiro Director | Bought | 78,239 | $1.39 | $108,752 |
| 26 August 2026 | Guerrero Ramiro Director | Bought | 8,931 | $1.39 | $12,414 |
| 24 August 2026 | Guerrero Ramiro Director | Bought | 1,794 | $1.33 | $2,386 |
| 20 August 2026 | Guerrero Ramiro Director | Bought | 11,899 | $1.37 | $16,302 |
| 1 June 2026 | Vitoc Vlad Chief Executive Officer, Director | Bought | 72,700 | $1.39 | $101,053 |
| 1 June 2026 | Smith Stan Director | Bought | 75,000 | $1.34 | $100,500 |
| 1 June 2026 | Gryaznov Sergei Chief Scientific Officer | Bought | 2,000 | $1.35 | $2,700 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 23 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 7 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.